Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is projected to have a positive future with its wide product portfolio and potential for growth, alongside its potential for revenue of $332M and a 1.4x EV/Sales multiple in 2027. While facing challenges in its wound care segment due to reimbursement changes, the company's high number of Medicare patients with chronic/acute wounds provides a strong market. Additionally, the company's leadership and financials, despite setbacks in clinical trials and challenges for some treatments, make it a promising investment opportunity.

Bears say

Organogenesis Holdings is facing significant challenges in its skin substitute segment, which accounts for a majority of its product offerings. CMS reimbursement changes, which went into effect in 2026, have led to a significant decline in the market and have negatively impacted the company's financials. While the potential FDA approval of ReNu could unlock a multibillion-dollar market opportunity, the clinical data on this product has been mixed and it is uncertain if it will receive adequate coding, coverage, and commercialization. The company's financials and valuation will likely continue to be under pressure until the CMS headwinds are resolved and the company successfully navigates through this uncertain period.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.